Aqemia stands at the forefront of the next generation in pharmaceutical technology, revolutionizing the drug discovery process through the integration of quantum-inspired physics and advanced machine learning techniques. This innovative approach enables Aqemia to generate one of the world's fastest-growing drug discovery pipelines, aiming to scale the drug discovery process like never before.
At the core of Aqemia's technology is a unique combination of quantum physics algorithms and generative AI. Unlike traditional AI-based platforms that rely on experimental data for training, Aqemia's platform generates its own data from the earliest stages of drug discovery. This is made possible by leveraging over 12 years of research from prestigious institutions such as Oxford, Cambridge, and ENS/CNRS. The result is an unprecedented pace—10,000 times faster—and accuracy in guiding AI towards the discovery of innovative drug candidates.
Since its inception in 2019 as a deep tech spin-off from École normale supérieure, Aqemia has rapidly grown into a team of over 50 passionate individuals. The company has established and expanded collaborations with large pharmaceutical companies and initiated its own drug discovery pipeline, encompassing multiple projects from hit generation to in vivo assays. Aqemia's ambitious goal is to massively accelerate research projects, scaling to dozens of wholly or partly owned drug candidates. These candidates are intended to be placed into a constellation of biotech spin-offs to carry out clinical trials, thereby transforming the landscape of drug discovery.
Aqemia's recent achievements include a significant multi-year collaboration with Sanofi, valued at $140 million, and a successful Series A funding round that raised $60 million. These milestones underscore the industry's confidence in Aqemia's innovative approach and its potential to redefine the future of drug discovery. By combining deep physics with AI, Aqemia is not just discovering new drugs; it's building the most scalable biotech generator, poised to bring groundbreaking treatments to patients faster than ever before.
